Q-omics provides the consensus-scored CPNE7 profile across patient tissues and cancer cell-line models. CPNE7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CPNE7 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, CPNE7 RNA expression shows 15,658 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, COAD, and THYM as cancer lineages where CPNE7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPNE7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPNE7 survival associations across molecular data types. CPNE7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPNE7 RNA expression–survival associations across cancer types. High CPNE7 expression shows unfavorable associations in MESO, UVM, KIRC, ACC and OV, but favorable associations in BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CPNE7 RNA expression.
This table summarizes CPNE7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CPNE7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPNE7 shows higher tumor expression in COAD, KIRP, LUAD, STAD, LIHC and HNSC. The COAD box plot shows higher CPNE7 RNA expression in tumor versus normal tissue (log2 FC = +5.038, t-test p < 0.001).
This table shows molecular features associated with CPNE7 in patient tissues and cancer cell lines. In patient samples, CPNE7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CPNE7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
